CSF3 and cancer: Interestingly, the treatment of cancer patients with G-CSF in the form of pegfilgrastim, a pegylated recobinant form of G-CSF, is already approved to prevent neutropenia and is well-tolerated even in combination with rituximab [173,174,175,176].